A Study Evaluating the Efficacy and Safety of CKD-314 in Hospitalized Adult Patients Diagnosed With COVID-19 Pneumonia

Inclusion Criteria: * Men and women Aged ≥18 years * Hospitalized subjects who have confirmed COVID-19 infection and have evidence of pneumonia: * COVID-19 infection: SARS-CoV-2 positive confirmed by RT-PCR * Pneumonia: A reliable diagnosis of new lung infiltration on a chest CT scan or chest radiograph * Subjects within 72 hours after confirmed COVID-19 pneumonia * Subjects with a seven-category ordinal scale of clinical status of 4 (hospitalization, requiring supplemental oxygen) or 5 (hospitalization, requiring nasal high-flow oxygen therapy and/or noninvasive mechanical ventilation) * Subjects (or legally authorized representative) should be able to understand and agree to comply with the clinical trial and to provide a written consent document prior to initiation of any study procedure Exclusion Criteria: * Subject has a serious chronic disease * Subject requiring invasive mechanical ventilation at the time of screening * Subject with rapidly(within 3 days) deteriorating clinical condition according to the investigator's opinion * Subject who have a record of HIV or AIDS * Subject taking corticosteroids\[However, ① steroids being used for the treatment of Corona 19 (eg, Dexamethasone, etc.), ② topical steroids, ③ Patients who are administering inhaled steroids are not eligible for exclusion\] * Subject taking immunosuppressants/immunomodulators * Subject with liver cirrhosis whose Child-Pugh score is B or C * Subject with hyperkalemia (K\> 5.1mmol/L) * Subject who have liver disease abnormalities with ALT or AST \> 5 times ULN * Estimated glomerular filtration rate (eGFR) \< 30 ml/min * QTc \>500ms * Subject who have hypersensitivity to the investigational drug * Pregnant or lactating females * Subject who are not appropriate for the study, as the investigator's opinion